Sino Biopharm (01177) rose over 3%. As of the time of writing, it was up 3.09%, trading at HKD 6.68 with a turnover of HKD 149 million.
According to Zhitong Finance, Sino Biopharm (01177) rose over 3%. As of the time of writing, it was up 3.09%, trading at HKD 6.68 with a turnover of HKD 149 million.
In terms of announcements, on February 9, Sino Biopharm issued a notice stating that LM-302 (CLDN18.2 ADC), a National Class 1 innovative drug independently developed by Limin Pharmaceutical Technology (Shanghai) Co., Ltd. (Limin Pharma), a wholly-owned subsidiary of the group, is currently undergoing a Phase III registration clinical trial (LM302-03-101) for the treatment of locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma positive for CLDN18.2 in third-line and above settings. Patient enrollment has been successfully completed. Notably, LM-302 is the world’s first CLDN18.2 ADC drug to complete patient enrollment for a Phase III registration trial.
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Limin Pharma presented the latest research data on LM-302 in combination with Toripalimab for the treatment of gastric cancer. Among 41 evaluable patients, the objective response rate (ORR) was 65.9%, and the disease control rate (DCR) was 85.4%. In the subgroup of 32 patients with CLDN18.2 expression ≥25%, the ORR reached 71.9%, and the DCR reached 96.9%. Stratified analysis by PD-L1 expression showed an ORR of 63.3% in patients with PD-L1 CPS <1 and an ORR of 77.8% in patients with CPS ≥1. The study indicates that the LM-302 combination regimen demonstrates significant antitumor activity and manageable safety characteristics in CLDN18.2-positive patients.
